With global growth signals sending mixed messages and central banks taking a cautious approach on interest rates, many investors are looking for stocks where current prices already reflect a fair amount of uncertainty. That is where the Undervalued Stocks Based On Cash Flows screener can help, by highlighting companies that SWS DCF valuation suggests are trading below their estimated fair value despite solid cash flow potential. This article picks out 3 of the stocks from that screener, giving you a focused shortlist of ideas to research further if you are hunting for value grounded in underlying cash generation.

Kyndryl Holdings (KD)

Overview: Kyndryl Holdings is a global IT services company that runs and modernizes critical technology infrastructure for large enterprises, providing cloud, AI and data, cybersecurity, digital workplace and network services across industries such as finance, healthcare, public sector and telecom.

Operations: Kyndryl generates US$3.8b of revenue from the United States, US$2.3b from Japan, and the remaining US$9.0b from principal and strategic markets across other regions.

Market Cap: US$2.4b

Kyndryl Holdings attracts attention because it sits at the heart of large scale IT modernization, while its shares are priced as though much of that opportunity is uncertain. The company is pushing into higher margin cloud, AI and cybersecurity work through partnerships with hyperscalers like AWS and Google Cloud, yet still carries the drag of older, lower margin legacy contracts and a high debt load. Profit margins are currently thin at 1.3%, but analysts expect stronger earnings, supported by efficiency efforts and a shift toward more profitable contracts, even as recent earnings have declined and management tenure is short. The key issue for investors is whether Kyndryl’s expanding AI and cloud pipeline can outweigh its governance concerns and transition risks before the discount closes.

Kyndryl’s shift toward higher margin cloud and AI work could be masking a deeper story in its contracts, cash flows and debt profile, and the 4 key rewards and 1 important warning sign might clarify whether the current discount is hiding a bigger twist

AbbVie (ABBV)

Overview: AbbVie is a global biopharmaceutical company that develops and sells prescription medicines across immunology, oncology, neuroscience, aesthetics, eye care and gastroenterology, including widely used brands such as Skyrizi, Rinvoq, Botox and Vraylar.

Operations: AbbVie generates about US$62.8b in revenue from its innovative medicines and therapies business, with around US$47.6b reported from the United States and a segment adjustment of roughly US$15.2b.

Market Cap: US$414.8b

AbbVie stands out for investors because its newer immunology and neuroscience drugs like Skyrizi, Rinvoq and Vraylar are helping to offset pressure from older products such as Humira. Recent EU label expansions and new indications broaden the potential patient base in areas such as psoriasis, hepatitis C, CLL and migraine. The planned US$10.9b Apogee Therapeutics acquisition adds another late stage immunology asset as the company focuses more on high value biologics, even as earnings have been volatile, debt is high and the dividend is not fully covered by current earnings. With a rich pipeline, a relatively high P/E and meaningful risks around pricing, patent cliffs and R&D execution, AbbVie is the kind of complex opportunity where understanding the full risk and reward profile matters more than just watching the headline valuation.

AbbVie’s newer drugs and rich pipeline might be masking a very different risk reward balance than its headline P/E suggests, and the full 2 key rewards and 4 important warning signs could change how you see the story

WiseTech Global (ASX:WTC)

Overview: WiseTech Global develops and sells software that helps logistics companies plan, track and manage the movement and storage of goods worldwide, covering forwarding, customs, transport, warehousing and digital documentation. Its CargoWise platform and related tools are designed to connect shippers, freight forwarders and carriers so information flows more smoothly across the supply chain.

Operations: WiseTech Global generates revenue across its international footprint, with about US$450.7m from the Americas, US$254.8m from Asia Pacific and US$364.2m from Europe, the Middle East and Africa.

Market Cap: A$9.6b

WiseTech Global sits at the intersection of logistics and software, with AI enabled products, a new transaction based pricing model and the E2open acquisition all aimed at turning global supply chain complexity into long term recurring revenue. Yet earnings have recently declined 19.4%, margins have compressed from 27.3% to 15.2% and the enlarged group now carries higher debt that is not well covered by operating cash flow, all against a high P/E and governance concerns around founder related investigations and rapid board turnover. For investors, the tension between strong growth forecasts, mission critical software and these financial and governance risks is a key consideration when reviewing WiseTech Global in an undervalued cash flow screen.

WiseTech Global’s earnings slide, margin squeeze and higher debt may be masking a very different long term picture. The analysis report for WiseTech Global could reveal whether the real story is just getting started

The 3 stocks in this article are just a starting point. The full Undervalued Stocks Based On Cash Flows screener surfaces 681 more companies where discounted valuations meet compelling cash flow stories via the Undervalued Stocks Based On Cash Flows screener. Use Simply Wall St to identify, filter and analyze the specific catalysts and narratives that matter to you so you can focus on the highest conviction ideas in minutes instead of hours.

Take Control of Your Investment Journey

If AbbVie or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before Momentum Flies Past?

Fresh stock ideas can move from under the radar to full breakout before most investors even look twice. Use these curated screeners while it matters and get in early.

• Spot companies where strong balance sheets back the story and run them through the list of solid balance sheet and fundamentals (48 results) so you are not caught holding weak financials when sentiment shifts.
• Chase real earnings momentum in AI by scanning the 61 profitable AI stocks that aren't just burning cash and focus on businesses already funding growth with actual profits instead of relying purely on hype.
• Position for long term infrastructure themes by reviewing the 33 power grid technology and infrastructure stocks and find companies tied to grid upgrades that could benefit as electrification trends gather pace.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.